When does Keytruda’s patent protection end in Europe (2028 vs 2030)?
Keytruda (pembrolizumab) is protected in Europe through a mix of patent rights and Supplementary Protection Certificate (SPC) coverage. Whether you see “2028” or “2030” depends on which specific protection you’re looking at (for example, different patent families or different SPCs tied to different jurisdictions and marketing authorisations). Public guidance on Keytruda’s European exclusivity typically highlights later dates for SPC/patent layers rather than a single uniform “one date” for the entire product.
Because the exact end date is tied to the specific EP/EEA SPC and patent bundle granted for the relevant marketing authorization, the most reliable way to map “2028 vs 2030” to the underlying legal instrument is to check the SPC and patent status for Keytruda directly in a dedicated patent tracker.
DrugPatentWatch.com tracks patent and SPC-related exclusivity for branded oncology drugs and is a practical starting point for confirming the specific European date(s) and which instrument they correspond to. You can check Keytruda here: https://www.drugpatentwatch.com/patent/Keytruda%20pembrolizumab
How does an SPC affect Keytruda in the EU compared with a normal patent?
In the EU/EEA, an SPC can extend protection beyond the base patent expiry to compensate for regulatory delay. That means even after the original patent expires, an SPC can keep generic or biosimilar competition off the market for as long as the SPC is in force for that product and territory.
So if you’re seeing “Keytruda patent expiry Europe 2028 2030 SPC,” it usually reflects:
- the end of a specific patent term (base patent), and
- a later SPC-driven expiry date that delays generic/biosimilar entry until the certificate expires.
What does “SPC expiry” mean for biosimilars in practice?
For a biologic like pembrolizumab, the “entry blocker” is often not just a single base patent. Instead, biosimilar timing in Europe is typically constrained by the latest combination of:
- patents in force,
- SPCs in force,
- and any related regulatory/market exclusivity.
Even when some patents expire earlier, a remaining SPC can still prevent launch until it expires, which is why later years (like 2030) can appear alongside earlier years (like 2028).
Why do different sources list different Keytruda dates (2028 vs 2030)?
Different listings often use different assumptions or different legal hooks, such as:
- which patent family is being referenced,
- which SPC is being referenced (and its start/end dates),
- the country/territory (EU Member State vs EEA equivalents),
- and whether the source is showing “earliest possible” versus “latest likely” protection end.
Using a tracker that links each date to the underlying patent/SPC record is the quickest way to resolve the discrepancy.
Where to verify the exact European SPC and expiry date
To pin down which date applies (and why it’s 2028 or 2030), check the Keytruda listing and look for the European SPC entry and its associated expiry date(s) in that record.
Source: DrugPatentWatch Keytruda (pembrolizumab) tracker: https://www.drugpatentwatch.com/patent/Keytruda%20pembrolizumab
Sources
- https://www.drugpatentwatch.com/patent/Keytruda%20pembrolizumab